Biotech

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ — The 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026), jointly organized by the Hong Kong Biotechnology Organization and Reed Sinopharm Exhibitions, will take place from September 9 to…

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

Officials at Elsevier say the company is expanding LeapSpace, a research-grade AI workspace, with new agentic capabilities that help “researchers carry out an even greater range of tasks within their complex workflow to drive better outcomes with confidence.” The post New Agentic Capabilities for Tasks Across the Complete Research Workflow appeared first on GEN -…

Vijay Kumar, the acting head of the FDA office that oversees new gene therapies, is stepping down from his role after a year in the job.

Discover how precision oncology companies are using AI and patient-relevant biology to reduce clinical trial failures in cancer. The post Rethinking precision oncology drug development: AI and tumor biology for smarter therapeutic programs appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from…

Biotechnology : nature.com subject feeds **Innovative Unified Bilayer Membranes with Mechanically Reinforced Interface Pave the Way for Stage-Adaptive Bone Regeneration** *By [Your Name]* In a groundbreaking advancement in regenerative medicine, researchers have developed unified bilayer […]

BIOCENTURY | DEALSVC-BACKED KARTOS SELLS TO IPSEN IN BACKLOADED AGREEMENT: DEALS REPORTPlus: Novartis, Antares in discovery deal; Zymeworks buys Theravance; Germany-based Merck acquires tools company Bio-Techne; and more

Biotechnology : nature.com subject feeds

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.